Discovery of ONO-8590580: a novel, potent and selective GABAA α5 negative allosteric modulator for the treatment of cognitive disorders.
Charles River Discovery Research Services, Chesterford Research Park, Little Chesterford, Essex, CB10 1XL.
Ono Pharmaceutical Co. Ltd., Minase Research Institute, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan.
Charles River Discovery Research Services, Chesterford Research Park, Little Chesterford, Essex, CB10 1XL. Electronic address: [email protected]
- Published Article
Bioorganic & medicinal chemistry letters
- Publication Date
Sep 05, 2020
The identification and SAR development of a series of negative allosteric modulators of the GABAA α5 receptor is described. This novel series of compounds was optimised to provide analogues with high GABAA α5 binding affinity, high α5 negative allosteric modulatory activity, good functional subtype selectivity and low microsomal turnover, culminating in identification of ONO-8590580. Copyright © 2020 Elsevier Ltd. All rights reserved.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 09/12/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/32898695